is a fistula less expensive than a graft?
Post on 19-Mar-2022
3 Views
Preview:
TRANSCRIPT
Is a Fistula Less Expensive Than aGraft?
Gary A. Gelbfish, MD, FACS
Advanced Vascular Care, Brooklyn, NYAssistant clinical professor, Mt. Sinai, NY, NY
USRDS 2008
• Fistulas used for hemodialysis require lessintervention than grafts to maintain long termpatency.
• Fistulas used for hemodialysis typically lastlonger than grafts
Fistula
Graft
For every complex question, there is ananswer that is clear, simple and wrongH.L.Mencken 1880-1956
• Early thrombosis and ultimate non-maturation occur much moreoften with fistulas as compared to graft.
• BAM are more often performed on fistulas than grafts therebyincreasing early costs.
• Once mature, “crummy” fistulas require more frequentintervention over the long term
• Prolonged catheter use is an inevitable result and a significantcost when fistula maturation is prolonged in patients already ondialysis.
Why/when wouldn’t a fistula be better?
“Cumulative patency did not differ between fistulas and grafts;however, grafts necessitated more interventions to maintain functionalpatency.” …………..However, when primary failures were excluded,cumulative patency became significantly longer for fistulas than forgrafts for both first and subsequent accesses (61.9 versus 23.8 months[HR, 0.56; 95% CI, 0.43−0.74; P<0.001]
CJASN 2013
In conclusion, as compared with grafts, subsequent upper armfistulas are associated with a higher primary failure rate, moreinterventions to achieve maturation, longer catheter dependence, andmore frequent catheter-related bacteremia. However, once the accessis usable for dialysis, fistulas have superior cumulative patency thando grafts and require fewer interventions to maintain patency. J AmSoc Nephrol 18: 1936–1941, 2007. doi: 10.1681/ASN.2006101119
How successful are we in the US atestablishing a functional fistula?
13
AV
fistulaAV graft Catheter
All 62.5 18.4 19.2
Age
0-21 47.0 6.8 46.1
22-44 64.8 15.7 19.6
45-64 64.2 17.7 18.1
65-74 61.9 19.3 18.8
75+ 58.7 20.4 20.9
Sex
Male 68.7 14.2 17.1
Female 54.5 23.7 21.8
Race
White 64.3 13.6 22.1
Black/African American 56.9 25.4 17.7
Native American 73.3 12.1 14.6
Asian 67.2 16.7 16.1
Ethnicity
Hispanic 67.5 15.4 17.1
Primary Cause of ESRD
Diabetes 62.7 18.2 19.1
Hypertension 61.9 19.3 18.8
Glomerulonephritis 64.8 18.1 17.2
Cystic Kidney 69.5 16.9 13.7
Other Urologic 61.9 17.6 20.4
Other Cause 57.5 17.2 25.3
Unknown/Missing 61.4 17.6 21.0
Vol 2, ESRD, Ch 4
Table 4.2 Distribution of type of vascular access in use amongprevalent hemodialysis patients in 2013, from CROWNWeb data, December
2013
Data Source: Special analyses, USRDS ESRD Database. CROWNWeb data catheter=anycatheter use; fistula and graft use shown are without the use of a catheter. Abbreviations:AV, arteriovenous; ESRD, end-stage renal disease.
14
Vol 2, ESRD, Ch 4
Figure 4.6 Trends in vascular access type use among ESRD prevalent patients,2003-2014
Data Source: Special analyses, USRDS ESRD Database, and Fistula First data. FistulaFirst data reported from July 2003 through April 2012, CROWNWeb data are reported fromJune 2012 through December 2013. Abbreviations: AV, arteriovenous; ESRD, end-stagerenal disease.
2015 CMS report (2013 data)
Dopps
What prevents higher fistula rates?
Enrollment was stopped after 877 participants were randomized basedon a stopping rule for intervention efficacy. Fistula thrombosisoccurred in 53 (12.2%) participants assigned to clopidogrel comparedwith 84 (19.5%) participants assigned to placebo (relative risk, 0.63;95% confidence interval, 0.46-0.97; P = .018). Failure to attainsuitability for dialysis did not differ between the clopidogrel andplacebo groups (61.8% vs 59.5%, respectively; relative risk, 1.05;95% confidence interval, 0.94-1.17; P = .40).
gg1
Slide 18
gg1 gary gelbfish, 2/16/2016
1. Venous and arterial anatomy and quality ofvessels (size, thickening, calcification, lesions)
2. OBESITY (much longer maturation interval andadditional procedures)
3. Surgical judgement and talent
4. Interventional talent for maturation
Limitations of fistula success.
Average number of procedures/doctor6 AV access CPT codes
<1% perform >170 procedures/year
Adapted from 2012 CMS Data
Not all patients are the same regardingsuitability and success of a fistula placement(obesity is a huge factor)
Not all surgeons have similar experience (andtalent) in vascular access.
• The average established fistula is better/cheaper thana graft in the long term
• It does NOT follow that we should TRY to implant afistula in every patient.
• A fistula that never matures (or takes prolonged &heroic measures to mature) should not be implanted.
• Fistula should be CONSIDERED in patients
1. Pick the right patients
2. Pick the right type of fistula
3. Use a surgeon with judgement to chose andtechnical talent to execute the right operation
4. Same with interventional talent to BAM
5. Avoid procedures that are destined to fail
Highest economical fistula rate is notaccomplished by putting fistulas in allpatients. Instead:
What is the true cost of a fistula or graft?
Cost of implantation
+ cost of failed attempts (5%)
+ cost of ultimate maintenance/thrombectomy procedures
Graft Cost
Cost of creation (intention to treat)
+ cost of failed attempts (20%-60%)
+ cost of balloon assisted maturation (successful and failed)
+ cost of ultimate maintenance/thrombectomy procedures
+ cost of prolonged catheter use
– (CRBSI)
– damage to central venous system andsubsequent intervention
Fistula Cost
30Vol 2, ESRD, Intro
Figure i.8 Vascular access use during the first year of hemodialysis by timesince initiation of ESRD treatment, among patients new to hemodialysis in
2013, from the ESRD Medical Evidence form (CMS 2728) and CROWNWebdata, 2013-2014
Data Source: Special analyses, USRDS ESRD Database. Medical Evidence form (CMS 2728)at initiation and CROWNWeb for subsequent time periods. Abbreviations: CMS, Centers forMedicare & Medicaid; ESRD, end-stage renal disease. This graphic is also presented asFigure 4.7.
2015 CMS report (2013 data)
Fistula Graft
Cost of creation +Cost of failed creation attempts ++Cost of Balloon assisted maturation ++
Cost of ultimate accessmaintenance/thrombectomy
+++
Cost of prolonged catheter use ++
Impact from physician experience ++
Impact from patient population factors ++
Longevity +
USRDS 2008
• Good data exists regarding the performance ofa given access type once established
• Patient specific parameters are important butseem to get lost in recommendations ofdecision making. Some patients are clearlymore difficult (Obesity, bad vessels/anatomy)
• Surgical judgment and skill is important, andcan help avoid wasted fistula effort (Logic)
• Financial data regarding overall cost isexceedingly poor
Current status: fistula vs. graft
Road forward
• Better definition of all relevant parameters
• More financial and other data, in cooperationwith Crownweb and CMS
• More experience in access placement forindividuals surgeons
• More studies
• Individualize therapy to patient
Robbin ML, Greene T, Cheung AK, Allon M, Berceli SA, Kaufman JS, Allen M, Imrey PB, Radeva MK, Shiu YT,Umphrey HR, Young CJ, Group FT. Arteriovenous Fistula Development in the First 6 Weeks after Creation. Radiology.2015 Dec 22:150385.Farber A, Imrey PB, Huber TS, Kaufman JM, Kraiss LW, Larive B, Li L, Feldman HI; HFM Study Group. Multiplepreoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study. JVasc Surg. 2016Jan;63(1):163-170.e6. doi: 10.1016/j.jvs.2015.07.086.
• When is it not in our power todetermine what is true, we aught toact in accordance with what is mostprobable…. Descartes 1596-1650
• Use a “patient centric and local reality” approach withemphasis on decreasing catheter interval and cost.
• CONSIDER using a fistula in all.
• Implant graft in few/some/many?
Summary:
• The essence of maximizing the inherentbenefit of a fistula vs. a graft, is to avoid earlypostop thrombosis and to minimizematuration procedures and prolonged catheterdialysis
• The lack of accurate cost data and thevariability of patient populations andsurgical/interventional talent make this goaldifficult to define and execute.
• To identify those patients or circumstanceswhere trying for a fistula is not indicated.
• To maximize intrinsic fistula benefit withoutwasting effort on fistulas that will fail or cannotbe matured in a reasonable way.
• To decrease catheter use interval.
Challenge
Data types• Please enter
Road forward
• Limited value of retrospective data, especiallyin a technologically evolving discipline. Usefulto tell us that things are a mess!
• Limited value of randomized studies especiallywith wide variations in patient populations,acess to care and of surgical and interventionalability
• Expansion of CrownWeb type data AND ENDUSER ACCESS, to assist in the analysis ofcomparative quality parameters
• Second year was more expensive than first year• Transposed basilic vein fistula is least expensive• Only analyzed established fistulas
• Current measures
Percent fistula/graft/catheter
Percent catheter over 90 days
• Future measures on query-able groups of patients
Onset of dialysis to first access use or to permcathremoval
Cost of access care including hospitalizations
Number of open procedures per patient
Number of interventional procedures per patient
Quality measures “Crownweb”
• Would need opening of medical database for researchand comparison purpose
• Individual patient or practice statistics are inadequateto describe outcomes that occur over years withmultiple practitioners.
• No incentive to really innovate without this
• Current setup is ripe for scamming.
Quality measures Crownweb
Where are we and why are we here?
• Dopps
• Fistula first
• Failure rates of fistulae
• Current fistula rates
• Maintenance costs
• Future directions
• A wise man’s question contains halfthe answer Solomon Ibn Gabirol 1021-1058
We can only review concepts and trends. Exactrecommendation are not possible considering:
• Inter-patient variability that has not been quantified.
• Methodological limitations, leading to lack of gooddata regarding outcomes and cost.
• Significant differences in skill levels amongstsurgeons and interventionalists.
• Prompt access to care and scheduling challenges
Access creation and maintenance is still an art!
In which cases are the up-frontinvestments worth the ultimate payback?
1. Stay within your technical competence level and grow over time
2. Have a sonogram machine in the OR and use it for your surgical decision making
3. Don’t be afraid to put in a graft as needed. Resist coercion.
4. Match the operation to the patient and their access history and future needs
5. Gauge your available interventional talents for maturation and then match yoursurgical actions
6. Decide early whether an access is likely to mature. 1-2 weeks is usually sufficient toknow.
7. Plan intervention early when needed (4-6 weeks after fistula creation)
8. Access creation and maintenance is still very much an art. Practice and learn fromothers!
9. Learn from you experience and hone your judgement by diligent long-term patientfollow up and meticulous records!
10. Learn how to examine the patient. There is no substitute to the physical exam
Recommendations
1. How hard should one try to place a fistula? Are wetrying too hard and making wrong choices?
2. What parameters should be used to abandon a fistula?
3. What are the cost implications? Which financialcategory do maturation and other wasted procedures gointo?
4. What patient or physician factors should influenceaccess choice?
• An established fistula is better than a graft• An established graft is better than a fistula that
never matures.
Why do we need crownweb• Dopps is a voluntary sample that ostensible
describes a larger group. It confidence level isunknown. It has a documentred propensity tounder or overestimate certain parameters (68%vs 62.5%) much quicker use of a dialysis fistulathan crownweb.
• Crownweb is real data on every patient
• Crownweb can access reimbursement data andto consolidate procedures performed inmultiple institutions
miscelaneous• Tremendous hole of knowledge in the middle
of whento do graft vs fistula
• Improvement in fistula rates
• Early referral, education of newer techniquestanspostions and elevations
• Number of procedures and cost of access perpatient
• Specializaion of surgeons.
• Availabailty and competitition amongstprovodrs with accurate cost and other milestonedata. Otherwise, low priority.
top related